UgandaTuberculosis profile
Population  2015 39 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.5 (3.3–8.3) 14 (8.5–21)
Mortality (HIV+TB only) 6.4 (1.7–14) 16 (4.3–36)
Incidence  (includes HIV+TB) 79 (47–119) 202 (120–304)
Incidence (HIV+TB only) 26 (16–37) 66 (42–94)
Incidence (MDR/RR-TB)** 1.9 (1–2.8) 4.9 (2.6–7.2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 3.2 (1.2–5.3) 23 (5.8–41) 27 (7–46)
Males 3.8 (2.2–5.3) 48 (32–64) 52 (34–70)
Total 7 (4.5–9.5) 72 (52–91) 79 (47–119)
TB case notifications, 2015  
Total cases notified 43 736
Total new and relapse 41 912
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 53% (35–89)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.16 (0.07–0.31)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 17 642 42%
          - on antiretroviral therapy 15 448 88%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 000
(660–1 400)
Estimated % of TB cases with MDR/RR-TB 1.6% (0.78–2.4) 12% (5.9–18)  
% notified tested for rifampicin resistance 8% 37% 6 827
MDR/RR-TB cases tested for resistance to second-line drugs   252
Laboratory-confirmed cases MDR/RR-TB: 252, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 253, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 75% 43 628
Previously treated cases, excluding relapse, registered in 2014 67% 2 438
HIV-positive TB cases, all types, registered in 2014 73% 16 670
MDR/RR-TB cases started on second-line treatment in 2013 73% 214
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 38
Funding source: 4% domestic, 78% international, 19% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data